Robert Driscoll
Stock Analyst at Wedbush
(0)
# 4697
Out of 5,329 analysts
202
Total ratings
21.28%
Success rate
-20.99%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
RVMD Revolution Medicines | Reiterates: Outperform | 67 67 | 40.69 | 64.66% | 5 | Apr 28, 2025 | |
ZNTL Zentalis Pharma | Reiterates: Neutral | 4 4 | 1.46 | 173.97% | 10 | Mar 28, 2025 | |
GLUE Monte Rosa Therapeut... | Maintains: Outperform | 15 17 | 4.9 | 246.94% | 4 | Mar 21, 2025 | |
HOWL Werewolf Therapeutic... | Reiterates: Outperform | 8 8 | 0.87 | 819.54% | 2 | Mar 12, 2025 | |
ARVN Arvinas | Downgrades: Neutral | 57 12 | 7.24 | 65.75% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 32 32 | 7.63 | 319.4% | 6 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 34 36 | 6.48 | 455.56% | 8 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 52 52 | 20.47 | 154.03% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 28 28 | 10.48 | 167.18% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 16 16 | 1.72 | 830.23% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 30 30 | 8.63 | 247.62% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 25 22 | 1.33 | 1554.14% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 85 51 | 7.54 | 576.39% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 5 5 | 0.63 | 693.65% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 36 36 | 8.54 | 321.55% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 11 11 | 1.81 | 507.73% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 13 13 | 4.17 | 211.75% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 11 13 | 1.42 | 815.49% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 74 74 | 32.1 | 130.53% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 12 12 | n/a | n/a | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 8 8 | 1.84 | 334.78% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 7 7 | 1.42 | 392.96% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 65 | n/a | n/a | 8 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 3 8 | 0.76 | 952.63% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 8 8 | 0.34 | 2252.94% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 52 | 9.66 | 438.3% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 4 1 | n/a | n/a | 4 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 3 | n/a | n/a | 3 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 36 | n/a | n/a | 2 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 50 70 | n/a | n/a | 4 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 9 2 | n/a | n/a | 2 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 136 17 | n/a | n/a | 3 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 5 9 | n/a | n/a | 6 | Jun 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 2 4 | 3.6 | 11.11% | 4 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 1500 250 | n/a | n/a | 1 | Mar 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 17 3 | n/a | n/a | 3 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 30 34 | n/a | n/a | 1 | Apr 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 120 160 | n/a | n/a | 1 | Feb 22, 2017 |